$BFLY

DEVIVO JOSEPH sold $359K of BFLY

DEVIVO JOSEPH (President & CEO) sold 35,790 shares of Butterfly Network, Inc. (BFLY) at $10.02 ($0.36M total) on 2026-10-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · DEVIVO JOSEPH
Published Oct 8, 2026, 9:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 9:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BFLY
Bearish
medium confidence
Mentioned
$BFLY
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BFLYBearishLow
01

Why it matters

The disclosed sale reduces the CEO's holdings to 7.3 million shares, a modest decrease that may affect perception.

02

Market read

The filing provides fresh insider activity data, offering a small but actionable insight for traders.

03

What to watch

The 10b5-1 plan pre‑arranged sale may have been scheduled before any material news.

Relevance 3/10Novelty 3/10Timing: after-hours filing

Background

Form 4 filings disclose insider transactions; a CEO sale is noteworthy for investors.

Company-level read

Ticker impact

$BFLYBearishMedium confidence
Context

President & CEO Devivo Joseph sold 35,790 shares for $358,615.80 via a 10b5-1 plan, reducing his stake.

Expected impact

likely pressure as the market prices in the insider sell

Evidence & confidence

The sale is modest but involves the CEO, which can be interpreted as a negative signal.

Market effects

Minimal impact on the medical imaging sector; the sale is company‑specific.

No broader regional effect.

Limited to investors tracking insider activity.

Counterpoint

The sale could be routine liquidity for personal reasons, not a negative signal.

Key entities

  • Butterfly Network, Inc.

    Medical imaging device maker listed on NASDAQ under BFLY.

  • Devivo Joseph

    President & CEO of Butterfly Network.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$QSIMed

2 Brain-Computer Interface Stocks to Watch While Neuralink Stays Private

Neuralink, a private brain-computer interface (BCI) company, successfully helped a patient with ALS communicate. Investors cannot buy Neuralink, but two public companies, Quantum-Si (QSI) and Butterfly Network (BFLY), are connected to the BCI field. QSI makes research tools and saw a 7x volume spike, while BFLY supplies ultrasound chips to BCI developers like Merge Labs and Bridge Neurotech.

$BFLYHigh

Why is Butterfly Network stock climbing today?

Butterfly Network (BFLY) stock rose 1.6% pre-market after Canaccord Genuity initiated coverage with a Buy rating and $10 target, citing its ultrasound tech and AI capabilities. Analysts highlight new products and partnerships. The stock has seen positive analyst activity, with a consensus target of $11.40. Q3 earnings are due October 29.

$BFLYHigh

Evercore ISI initiates Butterfly Network stock with outperform rating

Evercore ISI initiated coverage on Butterfly Network (NYSE: BFLY) with an outperform rating and $15.00 price target, citing its ultrasound-on-chip technology and growth potential. The firm projects $550M+ revenue by 2030 and positive EBITDA by 2028. BFLY stock has risen 367% over the past year, trading at $9.15 with a $2.44B market cap. Q2 2026 results showed a smaller loss than expected but lower revenue. Needham also initiated coverage with a buy rating and $10.00 target.

$BFLYHighAI 8/10

Why is Butterfly Network stock surging today?

Butterfly Network (BFLY) stock rose 11.5% after Needham initiated coverage with a Buy rating and $10 target, citing its ultrasound tech and Embedded business model. TD Cowen also has a Buy rating and $10 target. BFLY's Q3 revenue grew 39% YoY, with Embedded segment growth and expanding margins. The broader market had minimal impact on BFLY's surge.

$BFLYMed

Butterfly Network at Morgan Stanley conference: platform push widens reach

Butterfly Network (BFLY) presented its strategy at Morgan Stanley's conference, shifting from handheld ultrasound to a semiconductor imaging platform. The company reported 20% revenue growth, with $112M in last 12-month revenue, and highlighted partnerships like Midjourney. It aims to expand its addressable market to $250B through its Butterfly Embedded model. The company expects a fourth-generation chip in 2027 to improve image quality and challenge competitors. Management emphasized its strong